Our products Pharmacovigilance Research The Team Contact us [FR] [DE] Gen-Orph Providing patients and physicians with effective and high quality medicines Learn more Our mission Easy access to effective, useful and effective medicines. Gen.Orph obtained successfully the pharmaceutical status in March 2017. Operational start was in January 2018. Gen.Orph focuses all it’s efforts on the healthcare of national and international patients : - Medicines for Orphan disease, that are effective and affordable - Medicines with attractive medical and economic potential - Innovative medicines for common diseases Our products Our orphan drugs for the treatment of rare diseases GEN-ORPH 1 Miglustat GEN-ORPH Treatment of Iysosomal storage disorders Indications: Gaucher disease Typ 1 Niemann-Pick Typ C disease Launches: 2018: France, Sweden, Norway and Finland 2019: Italy, Bulgaria and Germany 2020: Portugal, Serbia, Czech Republic, Ungary, Poland, Slowakia, Slowenia, England, Greece, Austria, Saudi Arabia and Latin America GEN-ORPH 2 Cinacalcet GEN-ORPH Orphan Drug for the treatment of rare diseases Indications: Secondary hyperparathyroidism in patients with dialysis kidney failure associated with Phosphate binders and vitamin D, since September 2017 also approved for children over the age of three Hypercalcemia in parathyroid carcinoma Cinacalcet Gen.Orph is about to register in some European countries Launches: Q2 2020, after patent expiry of the original preparation GEN-ORPH 3 Orphan drugs for the treatment of rare diseases Gen.Orph 3 is under development and gets into a decentralized process registered at European level. Launch planned in Q4 2020 To consult the summary of the characteristics produced, the notice, the opinion of the Transparency Commission, refer to the following link: http://base-donnees-publique.medicaments.gouv.fr/ Other Commercialized Products from Gen.Orph Agyrax, Postafen, Navidoxine Meclozine Chlorhydrat Available in France, Sweden, Norway, Finland, Danmark, Iceland, Malta, Senegal and Ivory coast. Indications: Prevention and treatment of motion sickness Treatment of dizziness Treatment for nausea and vomiting pregnant women in Sweden. Sitavig Aciclovir Lauridad Launched in the US, Italy and France Indications: Treatment of recurring herpes simplex in patients with frequent episodes. PHARMACOVIGILANCE All medicines can have side effects. If you suspect any side effect, whether or not it is listed in the package leaflet, talk to your doctor or pharmacist. This also applies to any effect that is not mentioned in the package leaflet. You can also report suspected adverse reactions directly via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM): www.signalement-sante.gouv.fr Our laboratory is at your service to provide you with any information concerning our specialties. To report an adverse reaction or have medical information, you can reach us by email: PR@gen-orph.com or by phone: +33 (0) 1.47.71.04.50 General Data Protection Regulation GEN-ORPH respects your privacy and protects your personal information. Your personal data will be processed in accordance with the notices on data in the European Economic Area concerning medical information, product information and the safety of medicinal products. If you have questions about the use of your personal information by GEN-ORPH or would like to receive them by e-mail or post, please contact us by e-mail or telephone. Interests between the pharmaceutical companies and health professionals / and other stakeholders in the healthcare system will be published on the Internet in accordance with the law of 29 December 2011 on health security and its decree of 21 May 2011, which will improve the transparency of the entire health system. Research and Development Further products are currently in the development phase The Team Etienne Jacob CEO Founder Medical doctor Pitié-Salpetriere, Paris Harvard Business School – AMP Patrice Layrac Director Founder Master in Economics at the Universität de Paris Dauphine et IEP INSEAD Eric Lille CFO Dr. A.M. Charrier Regulatory Affairs Jocelyn Lejay Responsible Person back up Franck Grodenic Responsible person industriel Anna Biedermann Commercial Management and Supply Chain Etienne Horreard Responsible Person Contact us 1 rue royale, 92210 Saint-Cloud +33(0)147710450 contact@gen-orph.com Name Email Message Submit Genorph © 2017 Utilisation des Cookies Nous utilisons des cookies pour assurer une expérience de navigation fluide. En continuant, nous supposons que vous acceptez l'utilisation des cookies. Accepter En savoir plus